findmyKOL

Keith Colburn, MD

Basic profile

Loma Linda University Medical Center

ORCIDNone on fileNPI
RegionLoma Linda, CA · WestSpecialtyRheumatologyFocusRheumatology/Immunology
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2015Online presenceNot yet checkedPayments2021 onwardNIH funding1989–1991Why? →

Keith Colburn is a Rheumatology/Immunology physician affiliated with Loma Linda University Medical Center. OpenAlex indexes 44 publications with 432 citations (h-index 14).

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
44publications

Distinct works indexed by OpenAlex.

432citations

Total citations across indexed works.

14h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
26companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments
1NIH grants · 1989–1991

Federally funded research awards.

View funding

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

11370 Anderson St
Ste 3150
Loma Linda, CA 923543450

Telephone

909-558-2191

Registry record last updated 8 Jul 2007.

View the NPPES registry record

Industry payments

26 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    31.8%
    SNRI8.8%
    Duloxetine Hcl94%Savella6%
    Part D<11 patients
    Nonergot Dopamine Agonist5.6%
    Ropinirole Hcl60%Pramipexole Dihydrochloride40%
    Part D20 patients

    + 8 more classes in this area

  • Musculoskeletal

    22.5%
    Muscle Relaxant9.3%
    Cyclobenzaprine Hcl78%Methocarbamol22%
    Part D70 patients
    gamma-Aminobutyric Acid-ergic Agonist5.5%
    Baclofen100%
    Part D55 patients

    + 4 more classes in this area

  • Cancer & immunology

    18.7%
    Folate Analog Metabolic Inhibitor7.1%
    Methotrexate100%
    Part D45 patients
    JAK inhibitor4.3%
    Rinvoq100%
    Part D23 patients

    + 6 more classes in this area

Where care is delivered (Part B), 20200% facility · 100% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 19891991 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

39 more publications behind the reveal.Reveal →

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”